½ÃÀ庸°í¼­
»óǰÄÚµå
1796855

Ä¡·áÀû Ç÷Àå ±³È¯(TPE) ½ÃÀå : ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø - Á¦Ç°º°, ±â¼úº°, ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÎ¹®, °æÀï(2020-2030³â)

Therapeutic Plasma Exchange Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Indication, By End User, By Region and Competition, 2020-2030F

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: TechSci Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ä¡·áÀû Ç÷Àå ±³È¯ ¼¼°è ½ÃÀåÀº 2024³â¿¡ 16¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ Áß ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 7.77%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 25¾ï 7,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Ä¡·áÀû Ç÷Àå ±³È¯(TPE)Àº ÇöóÁ Æä·¹½Ã½º(Plasma Feresis)¶ó°íµµ Çϸç, °í°´ÀÇ Ç÷¾×¿¡¼­ º´¿ø¼º ¹°ÁúÀ» ºÐ¸®ÇÏ¿© ¾ËºÎ¹Î ¿ë¾×À̳ª ½Å¼±µ¿°áÇ÷Àå µîÀÇ ´ëü¾×À¸·Î ´ëüÇÏ´Â Ç÷°ü ³» Ç÷¾× ±â¼úÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹°Áú¿¡´Â °¨¿°¼º ÀÚ°¡Ç×ü, ¸é¿ªº¹ÇÕü, ¸é¿ª±Û·ÎºÒ¸°, ÄÝ·¹½ºÅ×·Ñ ÇÔÀ¯ Áö´Ü¹éÁú µîÀÌ Æ÷ÇԵ˴ϴÙ. TPE´Â ´Ù¾çÇÑ ÀÚ°¡¸é¿ªÁúȯ, ½ÅÀåÁúȯ, Ç÷¾×Áúȯ µîÀÇ Ä¡·á¿¡ »ç¿ëµÇ¾î ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ÀåÁ¡À¸·Î, TPE´Â Ç÷Àå Á¡µµ¸¦ ³·Ãß´Â Å« ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. Ç÷À屳ȯÀº ¸¸¼ºÁúȯ °ü¸®¿¡¼­ 1Â÷ ¶Ç´Â 2Â÷ ¼±Åà ¿ä¹ý ¶Ç´Â ÁöÁö¿ä¹ýÀ¸·Î ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Ç÷À屳ȯÀº µ¶¼Ò ¹× ±âŸ ºñÁ¤»óÀûÀÎ ¹°ÁúÀ» Æ÷ÇÔÇÑ Ç÷ÀåÀÇ »ó´ç ºÎºÐÀ» ´Ù¸¥ Ç÷¾× ¼ººÐ¿¡¼­ ÃßÃâÇÏ¿© ½Å¼±µ¿°áÇ÷Àå(FFP)À̳ª ¾ËºÎ¹Î°ú °°Àº ´ëü¾×À¸·Î ±³È¯ÇÕ´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â
½ÃÀå ±Ô¸ð : 2024³â 16¾ï 4,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 25¾ï 7,000¸¸ ´Þ·¯
CAGR : 2025³â-2030³â 7.77%
±Þ¼ºÀå ºÎ¹® Ç÷¾× Áúȯ
ÃÖ´ë ½ÃÀå ºÏ¹Ì

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

½Å°æÁúȯ, ½ÅÀåÁúȯ, Ç÷¾×ÁúȯÀÇ ³ôÀº À¯º´·ü

ÁÖ¿ä ½ÃÀå °úÁ¦

ÇöóÁ Æä·¹½Ã½º ½Ã¼ú¿¡ µû¸¥ À§Ç輺

ÁÖ¿ä ½ÃÀå µ¿Çâ

Áö¼ÓÀûÀÎ ¹ßÀü

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ Ä¡·áÀû Ç÷Àå ±³È¯(TPE) ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • Á¦Ç°º°(¼Ò¸ðǰ, µð¹ÙÀ̽º)
    • ±â¼úº°(¿ø½ÉºÐ¸®, ¸·ºÐ¸®)
    • ÀûÀÀÁõº°(½Å°æÁúȯ, Ç÷¾×Áúȯ, ½ÅÀåÁúȯ, ´ë»çÁúȯ, ±âŸ)
    • ÃÖÁ¾»ç¿ëÀÚº°(äÇ÷¼¾ÅÍ ¹× Ç÷¾× ¼ººÐ °ø±Þ¾÷ü, º´¿ø ¹× Áø·á¼Ò, ¼öÇ÷ ¼¾ÅÍ, ±âŸ)
    • Áö¿ªº°
    • ±â¾÷º°(2024³â)
  • ½ÃÀå ¸Ê

Á¦6Àå ºÏ¹ÌÀÇ Ä¡·áÀû Ç÷Àå ±³È¯(TPE) ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • ºÏ¹Ì : ±¹°¡º° ºÐ¼®
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ

Á¦7Àå À¯·´ÀÇ Ä¡·áÀû Ç÷Àå ±³È¯(TPE) ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • À¯·´ : ±¹°¡º° ºÐ¼®
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ä¡·áÀû Ç÷Àå ±³È¯(TPE) ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º° ºÐ¼®
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ

Á¦9Àå ³²¹ÌÀÇ Ä¡·áÀû Ç÷Àå ±³È¯(TPE) ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • ³²¹Ì : ±¹°¡º° ºÐ¼®
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ä¡·áÀû Ç÷Àå ±³È¯(TPE) ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ºÐ¼®
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦11Àå ½ÃÀå ¿ªÇÐ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • °úÁ¦

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

  • ÃÖ±Ù µ¿Çâ
  • ÀμöÇÕº´(M&A)
  • Á¦Ç° Ãâ½Ã

Á¦13Àå ¼¼°èÀÇ Ä¡·áÀû Ç÷Àå ±³È¯(TPE) ½ÃÀå : SWOT ºÐ¼®

Á¦14Àå PorterÀÇ Five Forces ºÐ¼®

  • ¾÷°è³» °æÀï
  • ½Å±Ô Âü¿© °¡´É¼º
  • °ø±Þ¾÷üÀÇ Èû
  • °í°´ÀÇ Èû
  • ´ëüǰÀÇ À§Çù

Á¦15Àå °æÀï ±¸µµ

  • Asahi Kasei Corporation
  • Baxter International Inc
  • B. Braun Melsungen AG
  • Cerus Corporation
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Hemacare Corporation
  • IncMedica S.p.A.
  • Kawasumi Laboratories
  • Terumo Corporation

Á¦16Àå Àü·«Àû Á¦¾È

Á¦17Àå ȸ»ç ¼Ò°³ ¹× ¸éÃ¥Á¶Ç×

LSH 25.09.01

Global Therapeutic Plasma Exchange Market was valued at USD 1.64 Billion in 2024 and is expected to reach USD 2.57 Billion by 2030 with a CAGR of 7.77% during the forecast period. Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an endovascular blood technique utilized to separate pathogenic substances from clients' blood and replace them with replacement fluid, such as albumin solution or fresh frozen plasma. These substances encompass infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is employed in the treatment of various autoimmune conditions, renal disorders, hematological disorders, and more, contributing to market expansion. Additionally, therapeutic plasma exchange (TPE) offers the significant benefit of reducing plasma viscosity. It is widely performed in the management of chronic diseases as a first-line or second-line therapy, or as a supportive treatment. During plasma exchange, a substantial portion of plasma containing toxins and other abnormal matter is extracted from the other blood components and replaced with replacement fluid, such as fresh frozen plasma (FFP) or albumin.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.64 Billion
Market Size 2030USD 2.57 Billion
CAGR 2025-20307.77%
Fastest Growing SegmentHematology Disorders
Largest MarketNorth America

Key Market Drivers

High prevalence of Neurological, Renal, And Hematological Disorders

The high prevalence of chronic diseases, such as nephrological disorders, acute liver failure, Guillain-Barre Syndrome (GBS), and others, contributes to the growth of the overall therapeutic plasma exchange market. Additionally, there has been a surge in the application of therapeutic plasma exchange, accompanied by intensive research and clinical trials to assess its efficacy compared to other treatments. These factors significantly bolster the growth of the therapeutic plasma exchange market. The most common indications for TPE therapy are nephrology-related disorders, as well as its use in the treatment of myasthenia gravis, Guillain Barre syndrome (GBS), and chronic inflammatory demyelinating polyneuropathy. Currently, the trend in therapeutic plasma exchange involves the use of highly permeable filters and standard dialysis equipment, often referred to as membrane plasma separation (MPS). In the US, the "Plasmaflo" membrane from Asahi Medical (Asahi Kasei Kuraray Medical Co., Ltd, Japan) is widely used.

Key Market Challenges

Risk Associated with Plasmapheresis Procedures

During the plasmapheresis procedure, a portion of blood is extracted from the human body, and specific replacement fluids like albumin, fresh frozen plasma (FFP), electrolyte solutions, purified protein products, and starches are administered intravenously to maintain intravascular osmotic pressure. Although generally considered safe, there are still several associated risks. Risk factors include infection, allergic reactions, hypotension, internal bleeding, electrolyte imbalance, and others. One of the most frequent side effects of plasmapheresis is hypotension, characterized by symptoms such as faintness, blurred vision, dizziness, sweating, or abdominal cramps. However, prompt treatment can effectively manage these symptoms. Some patients may experience numbness or tingling around the mouth or nose due to the effect of the anticoagulant citrate on calcium levels in the body. In rare cases, bleeding may occur during the procedure as a result of anticoagulants added to the blood, potentially leading to irregular heartbeat and cardiac arrest if not promptly addressed. Allergic reactions, itching, and rash may also occur as a response to the replacement fluids, but these can be easily treated with intravenous medication. These side effects may impede the widespread adoption of plasmapheresis, thereby limiting market growth to some extent.

Key Market Trends

Continuous Advancement

Continuous technological advancements have significantly enhanced and refined high-precision methods. These advancements not only improve patient satisfaction but also enhance the processing of goods derived from blood and plasma. In comparison to other techniques such as membrane separation methods, this method requires minimal blood flow, making it a more advanced approach for facilitating blood collection through the patient's antecubital or radial veins. Moreover, these technological advancements allow for more precise control of hydration status, resulting in greater hemodynamic stability during treatment. Additionally, patients benefit from improved comfort and safety during therapeutic plasma exchange (TPE) procedures. These remarkable technological developments create lucrative opportunities within the market.

Key Market Players

  • Asahi Kasei Corporation
  • Baxter International Inc
  • B. Braun Melsungen AG
  • Cerus Corporation
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Hemacare Corporation
  • IncMedica S.p.A.
  • Kawasumi Laboratories
  • Terumo Corporation

Report Scope:

In this report, the Global Therapeutic Plasma Exchange Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Therapeutic Plasma Exchange Market, By Product:

  • Consumables
  • Devices

Therapeutic Plasma Exchange Market, By Technology:

  • Centrifugation
  • Membrane Separation

Therapeutic Plasma Exchange Market, By Indication:

  • Neurological Disorders
  • Haematology Disorders
  • Renal Disorders
  • Metabolic Disorders
  • Others

Therapeutic Plasma Exchange Market, By End User:

  • Blood Collection Centres & Blood Component Providers
  • Hospitals & Clinics
  • Blood Transfusion Centres
  • Others

Therapeutic Plasma Exchange Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.

Available Customizations:

Global Therapeutic Plasma Exchange market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic Plasma Exchange Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Consumables, Devices)
    • 5.2.2. By Technology (Centrifugation, Membrane Separation)
    • 5.2.3. By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Others)
    • 5.2.4. By End User (Blood Collection Centers & Blood Component Providers, Hospitals & Clinics, Blood Transfusion Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Therapeutic Plasma Exchange Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Indication
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Therapeutic Plasma Exchange Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Indication
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Therapeutic Plasma Exchange Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Indication
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Therapeutic Plasma Exchange Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Indication
        • 6.3.3.2.4. By End User

7. Europe Therapeutic Plasma Exchange Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Indication
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Therapeutic Plasma Exchange Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Therapeutic Plasma Exchange Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Therapeutic Plasma Exchange Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By End User
    • 7.3.4. France Therapeutic Plasma Exchange Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Indication
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Therapeutic Plasma Exchange Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Indication
        • 7.3.5.2.4. By End User

8. Asia-Pacific Therapeutic Plasma Exchange Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Indication
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Therapeutic Plasma Exchange Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By End User
    • 8.3.2. India Therapeutic Plasma Exchange Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Therapeutic Plasma Exchange Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Therapeutic Plasma Exchange Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Therapeutic Plasma Exchange Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By End User

9. South America Therapeutic Plasma Exchange Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Indication
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Therapeutic Plasma Exchange Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Therapeutic Plasma Exchange Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Therapeutic Plasma Exchange Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By End User

10. Middle East and Africa Therapeutic Plasma Exchange Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By Indication
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Therapeutic Plasma Exchange Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Indication
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Therapeutic Plasma Exchange Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Indication
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Therapeutic Plasma Exchange Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Indication
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Therapeutic Plasma Exchange Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Asahi Kasei Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Baxter International Inc
  • 15.3. B. Braun Melsungen AG
  • 15.4. Cerus Corporation
  • 15.5. Fresenius Kabi AG
  • 15.6. Haemonetics Corporation
  • 15.7. Hemacare Corporation
  • 15.8. IncMedica S.p.A.
  • 15.9. Kawasumi Laboratories
  • 15.10. Terumo Corporation

16. Strategic Recommendations

17. About Us & Disclaimer

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦